Alcidion confirms FY26 revenue above $50 million and EBITDA over $5 million, completing the Kyra flow products acquisition from Telstra Health to expand its patient flow solutions in ANZ and the UK.
- FY26 revenue expected to exceed $50 million
- EBITDA forecast above $5 million
- Kyra acquisition adds 33 customers, mostly new
- Acquisition immediately earnings accretive pre-synergies
- Long-term contracts extend into mid-2030s
FY26 Guidance Reconfirmed Amid Record Performance
Alcidion Group Limited (ASX:ALC) has reinforced its FY26 financial outlook, projecting revenue to surpass $50 million and EBITDA to exceed $5 million. Operating cashflow is expected to remain broadly consistent with the previous year’s $5.8 million. This confidence stems from solid financial performance and substantial contracted revenue, including a significant upfront payment from a newly signed UK contract.
CEO Kate Quirke described FY26 as a record year, highlighting the strength of Alcidion’s long-term contracts, many of which extend into the mid-2030s. The company’s ability to secure upfront license fees, such as the recent deal with University Hospitals Sussex, has underpinned the firm’s earnings visibility and cash position.
Strategic Acquisition of Kyra Flow Products Completed
On 29 June 2026, Alcidion finalised the acquisition of Telstra Health’s Kyra flow products, including Kyra Patient Flow Manager, Kyra Queue Manager, and Kyra IQ. This deal brings 33 customers into Alcidion’s fold, 31 of whom are new, strengthening its footprint in Australia and the UK patient flow market.
The acquisition is immediately earnings accretive on a pre-synergy basis and is expected to open new growth avenues for Alcidion’s flagship Miya Precision platform. Initial customer feedback has been positive, with the company focusing on seamless integration and high service standards to retain momentum.
Market Position and Future Opportunities
Alcidion’s expanded portfolio now offers a more comprehensive suite of patient flow solutions, positioning it as a leading healthcare IT provider in its core markets. The company intends to maintain a collaborative relationship with Telstra Health to leverage complementary technologies.
With operations spanning Australia, New Zealand, and the UK, Alcidion is well placed to capitalise on growing demand for healthcare IT solutions that enhance patient care efficiency and outcomes. The Kyra acquisition complements recent contract wins, including a $35 million UK Electronic Patient Record deal, and supports the company’s trajectory towards sustained growth.
Bottom Line?
Alcidion’s FY26 outlook and strategic acquisition underscore its growing influence in healthcare IT, but integration execution and customer retention will be critical to unlocking full value.
Questions in the middle?
- How smoothly will Alcidion integrate Kyra’s products and customer base without disrupting service?
- What impact will the Kyra acquisition have on Alcidion’s recurring revenue profile in FY27 and beyond?
- Can Alcidion leverage its expanded platform to secure further large-scale contracts in the UK and ANZ?